1
|
The role of surgery in anaplastic thyroid cancer: A systematic review. Am J Otolaryngol 2017; 38:337-350. [PMID: 28366512 DOI: 10.1016/j.amjoto.2017.02.005] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2017] [Accepted: 02/26/2017] [Indexed: 11/21/2022]
Abstract
OBJECTIVE To elucidate the role of surgery in the management of anaplastic thyroid cancer. METHODS Ovid MEDLINE, Cochrane Library, and Google Scholar databases were searched for publications from December 2000 to July 2016. Selection criterion was a focus on the management of anaplastic thyroid cancer in adults. Studies addressing only nonsurgical management and review articles were excluded. Data extraction was performed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Kaplan-Meier analysis was performed on a subset of patients. RESULTS 40 publications were included in the study. Approaches to unresectability and interpretations of resection varied widely. For patients undergoing primary surgery, the median survival was 6.6months. The median survival for non-surgical patients was 2.1months. In the subgroup analysis, the median survival time for patients undergoing surgery was significantly longer in Stage IVB (p=0.022) but not IVC disease. Negative margins did not afford a statistically significant survival benefit. CONCLUSION Surgery is a mainstay of treatment for Stage IVA and IVB disease. For Stage IVC cancer, distant metastasis was not a strict criterion against surgical candidacy among surgeons. The extent of resection and the definition of resectability remain controversial. Negative margins did not significantly increase survival.
Collapse
|
2
|
Shi X, Liu R, Qu S, Zhu G, Bishop J, Liu X, Sun H, Shan Z, Wang E, Luo Y, Yang X, Zhao J, Du J, El-Naggar AK, Teng W, Xing M. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J Clin Endocrinol Metab 2015; 100:E632-7. [PMID: 25584719 PMCID: PMC4399285 DOI: 10.1210/jc.2014-3606] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT The aggressive role of TERT promoter mutations has been well established in differentiated thyroid cancer but has not been established in anaplastic thyroid cancer (ATC). RESEARCH DESIGN We tested the mutation status by sequencing genomic tumor DNA and examined its relationship with clinicopathological characteristics of ATC. RESULTS Among 106 American and Chinese ATC samples, TERT 1,295,228 C>T (termed TERT C228T) mutation was found in 37 (34.9%) cases, TERT promoter mutation 1,295,250 C>T was found in four cases (3.8%), and the two mutations were mutually exclusive and collectively found in 41 cases (38.7%). TERT C228T occurred in 28 of 90 (31.1%) wild-type BRAF cases vs nine of 16 (56.3%) BRAF V600E cases, with an odds ratio of 2.85 (95% confidence interval, 0.96-8.42; P = .05). Patient age was 67.6 ± 13.6 vs 61.6 ± 11.4 years in the TERT C228T vs wild-type TERT patients (P = .02), demonstrating an association between TERT C228T and older patient age. This association was also seen within the American cohort. In this cohort, which had more available clinicopathological data, TERT C228T was associated with distant metastasis of the tumor; specifically, distant metastasis occurred in 15 of 18 (83.3%) TERT C228T patients vs eight of 26 (30.8%) wild-type TERT patients, with an odds ratio of 11.25 (95% confidence interval, 2.53-50.08; P = .001). No association was found with patient sex, tumor size, lymph node metastasis, and extrathyroidal invasion of ATC. CONCLUSIONS This is the largest study on the aggressive role of TERT promoter mutations in ATC, demonstrating an association of TERT C228T with BRAF V600E, older patient age, and tumor distant metastasis in ATC.
Collapse
Affiliation(s)
- Xiaoguang Shi
- Laboratory for Cellular and Molecular Thyroid Research (X.S., R.L., G.Z., X.L., M.X.), Division of Endocrinology, Diabetes & Metabolism, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287; Department of Endocrinology & Metabolism (S.Q.), Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China; Department of Pathology (J.B.), The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287; Jilin Provincial Key Laboratory of Surgical Translational Medicine (H.S.), Department of Thyroid and Parathyroid Surgery, China-Japan Union Hospital, Jilin University, Changchun, Jilin Province 130033, China; Department of Pathology (E.W.), The First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province 110001, China; Department of Medical Image (Y.L.), Liaoning Cancer Hospital & Institute, Shenyang, Liaoning Province 110001, China; Department of Pathology (X.Y.), Shengjing Hospital of China Medical University, Shenyang, Liaoning Province 110004, China; Department of Endocrinology (J.Z.), Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong Province 250021, China; Department of Endocrinology (J.D.), The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province 116011, China; Department of Pathology (A.K.E.-N.), University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030; and The Endocrine Institute and The Liaoning Provincial Key Laboratory of Endocrine Diseases (X.S., Z.S., W.T.), Department of Endocrinology and Metabolism, The First Hospital of China Medical University, Shenyang, Liaoning Province 110001, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
A large nonmetastatic anaplastic thyroid cancer with complete thyroidal confinement. Case Rep Med 2011; 2011:583978. [PMID: 21912554 PMCID: PMC3170804 DOI: 10.1155/2011/583978] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2011] [Revised: 07/08/2011] [Accepted: 07/10/2011] [Indexed: 12/03/2022] Open
Abstract
Anaplastic thyroid cancer (ATC) is rare but extremely aggressive, which accounts for
about 2% of all thyroid cancers yet nearly 50% of thyroid-cancer-associated deaths
in the United States. The median survival time from diagnosis is 5 months, with a
1-year survival rate of only 20%. We report here a case of ATC in a 56-year-old man
who survived a large ATC. Preoperative fine-needle aspiration biopsy study to a
large right thyroid mass suggested ATC. Total thyroidectomy with radical lateral
neck and central neck dissection removed a well-circumscribed 9.5 cm tumor
without extrathyroidal extension or lymphovascular invasion. All 73 lymph nodes
removed were negative for metastasis. The tumor consisted of highly pleomorphic,
undifferentiated cells with large zones of necrosis and loss of thyroid
transcription factor-1 and thyroglobulin expression. A focal well-differentiated
component and PAX8 expression confirmed its thyroid follicular cell origin. Nine
months after postsurgical adjuvant concurrent radiation therapy and chemotherapy,
the patient remained well without clinical, biochemical, and radiographical evidence
for cancer recurrence. This is an unusual case of ATC in that it is one of the
largest ATC tumors reported to display mild pathologic behavior and relatively
long-term patient survival.
Collapse
|
4
|
Calò PG, Maxia S, Lai ML, Nicolosi A, Ribuffo D. Sclerosing Mucoepidermoid Thyroid Carcinoma Requiring Cervical Reconstruction: A Case Report and Review of the Literature. Am Surg 2010. [DOI: 10.1177/000313481007600850] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Pietro G. Calò
- Policlinico Universitario S. Giovanni di Dio Hospital University of Cagliari Cagliari, Italy
| | - Sara Maxia
- Policlinico Universitario S. Giovanni di Dio Hospital University of Cagliari Cagliari, Italy
| | - Maria L. Lai
- Policlinico Universitario S. Giovanni di Dio Hospital University of Cagliari Cagliari, Italy
| | - Angelo Nicolosi
- Policlinico Universitario S. Giovanni di Dio Hospital University of Cagliari Cagliari, Italy
| | - Diego Ribuffo
- Policlinico Universitario S. Giovanni di Dio Hospital University of Cagliari Cagliari, Italy
| |
Collapse
|
5
|
Rodier JF, Tuech JJ, Wilt M, Lindas P, Bruant-Rodier C. [A locally advanced intrathyroid metastasis of bronchial cancer]. ACTA ACUST UNITED AC 2008; 125:198-203. [PMID: 18755448 DOI: 10.1016/j.aorl.2008.07.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2007] [Accepted: 07/03/2008] [Indexed: 11/17/2022]
Abstract
PURPOSE To assess the characteristics, the diagnosis and the treatment of intrathyroid metastasis. METHOD The authors report a case of a locally advanced intrathyroid metastasis of a bronchial cancer. RESULTS A 60-year-old woman, treated seven years before for a well-differentiated bronchial adenocarcinoma, developed enlargement of the thyroid gland. Metastatic disease was confirmed by a surgical biopsy. Following incomplete radiochemotherapy, a palliative surgical debulking was performed, associating an isthmolobectomy with a large skin excision and closure with a pectoralis major myocutaneous flap. CONCLUSION Intrathyroid metastases are rare and usually treated by surgery. Surgical management is decided taking into account the type and the kinetics of the primary tumor, the location of the thyroid metastasis, and the extension of the metastatic disease. Except for isolated intrathyroid metastasis of kidney cancer, prognosis remains poor.
Collapse
Affiliation(s)
- J-F Rodier
- Département de chirurgie-oncologique, centre de lutte contre le cancer Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, BP 42, 67065 Strasbourg cedex, France.
| | | | | | | | | |
Collapse
|